The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 50 - 74 |
| Updated: | 4/2/2016 |
| Start Date: | January 2012 |
| End Date: | May 2012 |
| Contact: | Steven I Cohen, MD |
| Email: | sicppmd@cox.net |
| Phone: | 4012727799 |
Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
This is a review of previously published data from a large prostate cancer prevention study
known as REDUCE. It is the investigators intention to review whether prostate specific
antigen (PSA) velocity (change over time) will predict the presence of prostate cancer and
its grade and stage (severity).
known as REDUCE. It is the investigators intention to review whether prostate specific
antigen (PSA) velocity (change over time) will predict the presence of prostate cancer and
its grade and stage (severity).
This is a review of previously published data from a large prostate cancer prevention study
known as REDUCE that utilized a 5 ARI, dutasteride. It is the investigators intention to
review whether PSA velocity (change over time) will predict the presence of prostate cancer
and its grade and stage (severity) by two year biopsy. The investigator will review and
compare data to a previously published study of similar design with finasteride.
known as REDUCE that utilized a 5 ARI, dutasteride. It is the investigators intention to
review whether PSA velocity (change over time) will predict the presence of prostate cancer
and its grade and stage (severity) by two year biopsy. The investigator will review and
compare data to a previously published study of similar design with finasteride.
Inclusion Criteria:
- Men,
- 50-74 years old with elevated PSA (>=4) along with negative entry biopsy of the
prostate who had a subsequent biopsy by 24 months.
Exclusion Criteria:
- Any positive biopsy of the prostate indicative of cancer upon entry
We found this trial at
1
site
Click here to add this to my saved trials
